National Breast Cancer Foundation partnered alongside CancerCoachLive to present an educational webinar titled, “Navigating Treatment and Support for Triple-Negative Breast Cancer.” Below is some of the information presented by CancerCoachLive’s team for patients, loved ones, and caregivers facing metastatic triple negative breast cancer. Click here to watch the entire webinar.
Triple negative breast cancer is considered the most aggressive and hard-to-treat form of breast cancer. The term “triple-negative” comes from this type’s lack of three markers, or receptors, commonly found in other types of breast cancer. TNBC lacks receptors for:
Since TNBC lacks these three receptors, the cancer is less likely to respond to hormone therapy, a common form of breast cancer treatment. However, chemotherapy, among other options, is still an effective option for the treatment of TNBC.
Read more about triple negative breast cancer and prognosis.
Metastatic breast cancer (MBC) is classified as Stage 4 breast cancer. In MBC, the cancer has spread to other parts of the body, which usually includes the lungs, liver, bones, or brain. When TNBC spreads to other parts of the body, it is considered metastatic TNBC.
Although metastatic TNBC is not curable, it is usually treatable, with the focus being on quality of life for the patient. Several factors influence treatment selection for metastatic TNBC, including disease stage, histology (tissue structures), subtype, previous treatments, and patient preferences. The best treatment available is the one that is tailored to the patient’s specific disease, goals, tolerances, and quality of life.
Surgery and radiation are not primary treatments for metastatic TNBC—these treatment options are often used in early-stage disease. For metastatic TNBC, surgery and radiation are considered palliative options that may be used to shrink tumors to make them easier to treat.
Chemotherapy includes oral or IV medicines used to destroy cancer cells in order to shrink a tumor before or after surgery or after the tumor spreads.
Immunotherapy is a relatively new form of treatment for women with MBC. Immunotherapy helps the body’s own immune system fight the cancer. Pembrolizumab and atezolizumab are approved immunotherapy options for metastatic TNBC.
Targeted therapy is treatment directed towards specific markers. Targeted drugs often have less severe side effects than standard chemotherapy drugs. There are two types of targeted therapies currently available for TNBC: antibody-drug conjugates and PARP inhibitors.
It’s important to have open discussions with your doctor and care team about how you may feel before, during, and after starting treatment.
Questions to ask your doctor or care team when discussing treatment plans:
Some cancer treatment and medication side effects include:
If you experience these or other side effects for an extended period of time, contact your care team.
A clinical trial is an approved research study that some doctors believe has a strong potential to improve standard treatments. Clinical trials are often used to learn if a new treatment is more effective than currently available care. There are new ways to treat TNBC being investigated and researched all the time. Clinical trials have many advantages, including:
Check with your care team about the availability of clinical trials in your area.
As with all treatment options, each patient should work with their medical team to determine the best approach to treating their specific type and stage of breast cancer.
National Breast Cancer Foundation is here for you and your loved ones. Whether you need support, education, or help during treatment, we have a team dedicated to getting you the help you deserve.
This post has been produced in partnership with CancerCoachLive and MedLive and presented by Tiffany A. Traina, MD, FASCO; Sara Donahue, MPH, NP, AOCNP; and Jennifer Witt, RN, MSN, OCN, CBCN. The full webinar can be viewed here.
Donations are always appreciated, but there are lots of great ways to get involved.
